NASDAQ:RENB Renovaro (RENB) Stock Price, News & Analysis $1.31 +0.06 (+4.80%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.27▼$1.3350-Day Range$0.94▼$1.7552-Week Range$0.57▼$5.25Volume233,303 shsAverage Volume508,607 shsMarket Capitalization$193.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Renovaro alerts: Email Address Renovaro MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish4.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 5 Articles This WeekInsider TradingSelling Shares$479,127 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 starsMedical Sector859th out of 936 stocksPharmaceutical Preparations Industry403rd out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Renovaro.Read more about Renovaro's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.64% of the float of Renovaro has been sold short.Short Interest Ratio / Days to CoverRenovaro has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Renovaro has recently increased by 46.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenovaro does not currently pay a dividend.Dividend GrowthRenovaro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RENB. Previous Next 3.2 News and Social Media Coverage News SentimentRenovaro has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Renovaro this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Renovaro to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Renovaro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $479,127.00 in company stock.Percentage Held by Insiders21.72% of the stock of Renovaro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.41% of the stock of Renovaro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Renovaro's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Renovaro is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renovaro is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovaro has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Renovaro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.See here to see the full details. About Renovaro Stock (NASDAQ:RENB)Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Read More RENB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RENB Stock News HeadlinesJuly 20, 2024 | insidertrades.comInsider Selling: Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells 16,362 Shares of StockJuly 18, 2024 | insidertrades.comAnderson Wittekind William Sells 21,954 Shares of Renovaro Inc. (NASDAQ:RENB) StockJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.July 16, 2024 | insidertrades.comAnderson Wittekind William Sells 14,896 Shares of Renovaro Inc. (NASDAQ:RENB) StockJuly 9, 2024 | insidertrades.comRenovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $75,500.00 in StockJune 28, 2024 | insidertrades.comRenovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $22,006.50 in StockJuly 25 at 10:30 AM | morningstar.comRenovaro Inc RENBJuly 21, 2024 | americanbankingnews.comAnderson Wittekind William Sells 16,362 Shares of Renovaro Inc. (NASDAQ:RENB) StockJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.July 16, 2024 | americanbankingnews.comRenovaro Inc. (NASDAQ:RENB) Major Shareholder Anderson Wittekind William Sells 14,896 Shares of StockJune 14, 2024 | globenewswire.comRenovaro, Inc. Announces $10 million in Equity CommittedMay 24, 2024 | globenewswire.comRenovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer ImmunotherapyMay 24, 2024 | tmcnet.comBiotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032May 16, 2024 | finance.yahoo.comRenovaro Inc. (RENB)May 16, 2024 | investorplace.comRENB Stock Earnings: Renovaro Biosciences Reported Results for Q3 2024May 15, 2024 | washingtonpost.comRenovaro: Fiscal Q3 Earnings SnapshotApril 30, 2024 | globenewswire.comTransforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on FragmentomicsApril 24, 2024 | globenewswire.comRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics PartnershipSee More Headlines Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)10/07/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RENB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.59% Return on Assets-47.14% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.63Miscellaneous Outstanding Shares147,510,000Free Float115,467,000Market Cap$191.76 million OptionableOptionable Beta0.60 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesHon. Mark R. Dybul M.D. (Age 60)CEO, Director & Member of HBV Scientific Advisory Board Comp: $764.58kDr. Francois Binette M.Sc. (Age 60)Ph.D., COO and Executive VP for Research & Development Comp: $504.38kDr. Serhat GümrükcüCo-Founder & InventorMr. Simon Tarsh (Age 62)Interim Chief Financial Officer Mr. Greg Duczynski Ph.D.Senior Vice President for Clinical OperationsKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHABIVAX Société AnonymeNASDAQ:ABVXDianthus TherapeuticsNASDAQ:DNTHPhibro Animal HealthNASDAQ:PAHCEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 125,461 shares on 7/26/2024Ownership: 0.085%Anderson Wittekind WilliamSold 16,362 sharesTotal: $23,888.52 ($1.46/share)Anderson Wittekind WilliamSold 21,954 sharesTotal: $30,955.14 ($1.41/share)Anderson Wittekind WilliamSold 14,896 sharesTotal: $22,492.96 ($1.51/share)Anderson Wittekind WilliamSold 4,630 sharesTotal: $7,083.90 ($1.53/share)View All Insider TransactionsView All Institutional Transactions RENB Stock Analysis - Frequently Asked Questions How have RENB shares performed this year? Renovaro's stock was trading at $3.17 at the beginning of the year. Since then, RENB stock has decreased by 58.7% and is now trading at $1.31. View the best growth stocks for 2024 here. How were Renovaro's earnings last quarter? Renovaro Inc. (NASDAQ:RENB) posted its earnings results on Wednesday, May, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. Who are Renovaro's major shareholders? Renovaro's top institutional shareholders include Bank of New York Mellon Corp (0.09%). View institutional ownership trends. How do I buy shares of Renovaro? Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RENB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENB Stock Alerts